# A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

> **NCT06754501** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Tiragolumab

## Key facts

- **NCT ID:** NCT06754501
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-11
- **Primary completion:** 2027-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754501, "A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06754501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*